10-Minute Mushroom Trip? New Psilocybin IV Depression Treatment Could Be a Game Changer
Last reviewed and updated: August 20, 2026.
Key Takeaways
| The idea | An intravenous formulation of psilocin aims to deliver a much shorter psychedelic session than traditional oral psilocybin. |
| Why shorter matters | Long sessions tie up a clinic room and trained staff for hours, so shortening the experience is a direct path to lower cost and wider access. |
| The company now | Beckley Psytech became part of AtaiBeckley, which Eli Lilly agreed to acquire in July 2026 in a deal worth up to $3.8 billion. |
| Pipeline progress | AtaiBeckley’s lead candidate BPL-003 met its primary endpoint in a Phase 2b depression trial, with most participants ready for discharge at 90 minutes. |
| Still investigational | None of these short-duration treatments are FDA-approved. The early IV psilocin trial included only 6 participants with no placebo group, so it is a preliminary signal. |
Remember when taking magic mushrooms meant setting aside an entire day for deep introspection? The traditional psychedelic experience was long, intense, and often a personal journey of discovery. But a new approach might just change that, and turn an all day psilocybin experience into a quick, but effective, 10-minute mushroom trip.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Beckley Psytech’s Groundbreaking Trial
Beckley Psytech, a biopharma company, has tested a new intravenous (IV) formulation of psilocin, the active compound in magic mushrooms, in a Phase 2a clinical trial. The results are promising for patients suffering from major depressive disorder.
Instead of the usual 8 hours of soul-searching, patients received the treatment via IV for just 10 minutes. And the effects? Immediate and profound.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Here’s a breakdown of the Beckley Psytech study results and how they compare to traditional magic mushroom experiences
| Aspect | Beckley Psytech IV Psilocin Study | Traditional Magic Mushroom Experience | Impact on Legalization/Psilocybin Therapy |
|---|---|---|---|
| Treatment Duration | 10-minute IV infusion | 4-8 hours oral ingestion | Shorter treatment time makes it easier to integrate into clinical workflows, increasing the feasibility of broader use. |
| Effect Onset | Immediate effects (depression scores drop by 25 points by the next day) | Gradual onset, typically within 30-60 minutes | Quick relief may make psilocybin therapy more appealing for patients and clinicians, supporting faster adoption. |
| Full Remission | 4 out of 6 patients achieved full remission within 24 hours | Full remission is rare and typically occurs after long sessions and integration | The fast, measurable impact could lead to stronger arguments for psilocybin’s efficacy in clinical settings. |
| Recovery Time | Patients are ready to leave the hospital in about 2 hours | Recovery can take several hours to a full day, depending on the individual | Reduced recovery time could make psilocybin therapy more accessible and less disruptive to patients’ lives. |
| Sustained Benefits | Effects lasted for up to 3 months | Benefits may last a few days to weeks, with the need for repeated sessions | Long-lasting effects could make psilocybin a more effective treatment for depression, possibly encouraging wider acceptance and integration. |
| Practical Application in Healthcare | Fits into existing ketamine clinic protocols (rapid and efficient) | Requires specially trained therapists and dedicated space for long sessions | A treatment like this could help psilocybin become more mainstream, aligning with current clinical practices. |
| Regulatory Impact | Supports faster integration into healthcare, possible for broader use | Longer sessions and intensive therapy make it harder to scale | This study’s positive results with a quicker treatment timeline could support faster regulatory approval and broader psilocybin legalization. |
Why Does This Matter?
You might be wondering, how significant is this? After all, the trial involved just 6 participants and lacked a placebo group. However, the real breakthrough here isn’t just the results, it’s the practical application.
Psychedelic therapy is often seen as impractical due to the need for long sessions, specialized therapists, and controlled environments. But with Beckley’s IV treatment, psilocin could fit seamlessly into existing mental health practices, just like ketamine does today.
The Future of Psychedelic Medicine
Is this the future of psychedelic medicine? If the goal is to integrate psychedelics into mainstream mental health care, Beckley’s approach could pave the way. While the research is still in early stages, it’s a promising sign that psychedelics might soon be more accessible to those who need them most.
Short-Duration Psychedelics in 2026
An intravenous formulation of psilocin, the active metabolite of psilocybin, is designed to deliver a much shorter and more controlled experience than oral psilocybin. The practical stakes are bigger than they first appear. A traditional supervised session can occupy a clinic room and trained staff for six or more hours. That staffing load is a major reason supervised psychedelic therapy costs what it does. Cutting session length is one of the clearest routes to lower cost and wider access.
The developer behind this work has changed shape considerably since the original trial. Beckley Psytech combined with atai Life Sciences to become AtaiBeckley. In July 2026, Eli Lilly agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, the largest psychedelic acquisition on record. The short-duration approach now carries Big Pharma resources and commercial reach behind it. That backing shapes whether these formulations ever reach clinics at scale.
AtaiBeckley’s lead candidate is BPL-003, an intranasal 5-MeO-DMT for treatment-resistant depression. It met its primary endpoint in a Phase 2b trial, showing statistically significant improvement within two days and durable benefit of at least two months. Most participants also met discharge readiness at the 90-minute post-dose assessment, which supports the short-session thesis directly. All of this remains investigational. No short-duration psychedelic treatment has FDA approval, and access today runs through clinical trials.
Frequently Asked Questions
- Can a psychedelic session really take only 10 minutes?
- Some formulations aim to compress the experience dramatically. An intravenous formulation of psilocin is designed to produce a much shorter, more controlled session than oral psilocybin, which can last six hours or more. In one Phase 2b trial of a short-acting compound, most participants were ready for discharge 90 minutes after dosing.
- Why does session length matter for psychedelic therapy?
- Cost and access. A long session ties up a clinic room and trained staff for many hours, which is a major reason supervised psychedelic therapy is expensive. Shortening the session reduces the staff time and facility use each patient requires, making treatment cheaper to deliver and easier to scale.
- What happened to Beckley Psytech?
- Beckley Psytech combined with atai Life Sciences to become AtaiBeckley. In July 2026, Eli Lilly agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, the largest psychedelic acquisition on record. The deal gives the company’s short-duration psychedelic pipeline the resources and commercial reach of the world’s largest pharmaceutical company.
- Is IV psilocin available as a treatment?
- No. Intravenous psilocin and other short-duration psychedelic formulations are investigational and not FDA-approved. They remain in clinical development, and access would be through a clinical trial. The research is advancing quickly, especially now that a major pharmaceutical company has acquired the developer.
